CN113917024A - 一种检测体内九种精神科药物及其代谢物的试剂盒 - Google Patents
一种检测体内九种精神科药物及其代谢物的试剂盒 Download PDFInfo
- Publication number
- CN113917024A CN113917024A CN202111176732.2A CN202111176732A CN113917024A CN 113917024 A CN113917024 A CN 113917024A CN 202111176732 A CN202111176732 A CN 202111176732A CN 113917024 A CN113917024 A CN 113917024A
- Authority
- CN
- China
- Prior art keywords
- solution
- sample
- tdm
- detection tube
- kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002207 metabolite Substances 0.000 title claims abstract description 15
- 229940124811 psychiatric drug Drugs 0.000 title claims abstract description 10
- 238000001727 in vivo Methods 0.000 title claims abstract description 8
- 238000001514 detection method Methods 0.000 claims abstract description 68
- 239000000243 solution Substances 0.000 claims abstract description 48
- 239000012086 standard solution Substances 0.000 claims abstract description 40
- 238000002360 preparation method Methods 0.000 claims abstract description 27
- 210000002966 serum Anatomy 0.000 claims abstract description 24
- 239000003814 drug Substances 0.000 claims abstract description 20
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 16
- 238000001035 drying Methods 0.000 claims abstract description 15
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000012488 sample solution Substances 0.000 claims abstract description 14
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000012472 biological sample Substances 0.000 claims abstract description 8
- 235000019253 formic acid Nutrition 0.000 claims abstract description 7
- 210000004209 hair Anatomy 0.000 claims abstract description 7
- 238000013329 compounding Methods 0.000 claims abstract description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 27
- 229960004503 metoclopramide Drugs 0.000 claims description 23
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 22
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 claims description 21
- 239000000523 sample Substances 0.000 claims description 21
- 229960004170 clozapine Drugs 0.000 claims description 20
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 16
- 239000012224 working solution Substances 0.000 claims description 16
- 229960004431 quetiapine Drugs 0.000 claims description 14
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 claims description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- JNNOSTQEZICQQP-UHFFFAOYSA-N N-desmethylclozapine Chemical compound N=1C2=CC(Cl)=CC=C2NC2=CC=CC=C2C=1N1CCNCC1 JNNOSTQEZICQQP-UHFFFAOYSA-N 0.000 claims description 12
- 239000000047 product Substances 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 11
- 239000006228 supernatant Substances 0.000 claims description 11
- 229960003991 trazodone Drugs 0.000 claims description 11
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 claims description 11
- 210000004369 blood Anatomy 0.000 claims description 10
- 239000008280 blood Substances 0.000 claims description 10
- 238000007865 diluting Methods 0.000 claims description 10
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 10
- PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 claims description 9
- 229960003036 amisulpride Drugs 0.000 claims description 9
- NTJOBXMMWNYJFB-UHFFFAOYSA-N amisulpride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 claims description 9
- 239000007864 aqueous solution Substances 0.000 claims description 9
- 229960001785 mirtazapine Drugs 0.000 claims description 9
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 claims description 9
- 229960005017 olanzapine Drugs 0.000 claims description 9
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims description 9
- 229960001534 risperidone Drugs 0.000 claims description 9
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims description 9
- 230000014759 maintenance of location Effects 0.000 claims description 8
- 210000002381 plasma Anatomy 0.000 claims description 8
- 210000003296 saliva Anatomy 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 7
- 239000012452 mother liquor Substances 0.000 claims description 7
- 231100000640 hair analysis Toxicity 0.000 claims description 6
- 239000012528 membrane Substances 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 4
- 239000011550 stock solution Substances 0.000 claims description 4
- 238000012360 testing method Methods 0.000 claims description 4
- 238000000861 blow drying Methods 0.000 claims description 3
- 238000005374 membrane filtration Methods 0.000 claims description 3
- 238000001471 micro-filtration Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 229940001470 psychoactive drug Drugs 0.000 claims description 3
- 239000004089 psychotropic agent Substances 0.000 claims description 3
- 238000003556 assay Methods 0.000 claims description 2
- 238000007664 blowing Methods 0.000 claims description 2
- HQVFCQRVQFYGRJ-UHFFFAOYSA-N formic acid;hydrate Chemical compound O.OC=O HQVFCQRVQFYGRJ-UHFFFAOYSA-N 0.000 claims description 2
- SVWLIIFHXFGESG-UHFFFAOYSA-N formic acid;methanol Chemical group OC.OC=O SVWLIIFHXFGESG-UHFFFAOYSA-N 0.000 claims description 2
- 239000010413 mother solution Substances 0.000 claims description 2
- 238000005070 sampling Methods 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 239000012085 test solution Substances 0.000 claims description 2
- 238000009210 therapy by ultrasound Methods 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 15
- 238000000926 separation method Methods 0.000 abstract description 9
- 238000000622 liquid--liquid extraction Methods 0.000 abstract description 2
- 238000000638 solvent extraction Methods 0.000 abstract description 2
- 239000012071 phase Substances 0.000 description 7
- 239000000164 antipsychotic agent Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 2
- 229940005529 antipsychotics Drugs 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 102000004108 Neurotransmitter Receptors Human genes 0.000 description 1
- 108090000590 Neurotransmitter Receptors Proteins 0.000 description 1
- 208000020114 Schizophrenia and other psychotic disease Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003693 atypical antipsychotic agent Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 230000004620 sleep latency Effects 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
- G01N30/14—Preparation by elimination of some components
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/28—Control of physical parameters of the fluid carrier
- G01N30/30—Control of physical parameters of the fluid carrier of temperature
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/28—Control of physical parameters of the fluid carrier
- G01N30/32—Control of physical parameters of the fluid carrier of pressure or speed
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/28—Control of physical parameters of the fluid carrier
- G01N30/34—Control of physical parameters of the fluid carrier of fluid composition, e.g. gradient
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/74—Optical detectors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/28—Control of physical parameters of the fluid carrier
- G01N30/32—Control of physical parameters of the fluid carrier of pressure or speed
- G01N2030/324—Control of physical parameters of the fluid carrier of pressure or speed speed, flow rate
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
本发明提供了一检测体内生物样本中九种精神科药物或其代谢物的试剂盒,包括:(一)混合标准品溶液TDM检测管,其制备方法包括:将内标溶液、混合标准品溶液加入TDM检测管中,干燥即得;(二)检测样品溶液TDM检测管,其制备方法包括:将内标溶液加入所述TDM检测管中,干燥即得;(三)复溶液:含甲酸的甲醇‑水溶液;(四)说明书:所述说明书记载了该试剂盒的使用方法;且所述试剂盒保存在‑20~‑15℃下。本发明采用液‑液萃取、内标UPLC‑UV法实现了人血清或头发中精神科常用药物及其活性代谢物的分离,大大缩短了检测时间的同时,还具有良好的临床检测价值与经济意义,具有良好的应用前景。
Description
技术领域
本发明涉及精神科药物血药浓度的检测领域,具体涉及检测体内九种精神科药物及其代谢物的试剂盒。
背景技术
抗精神病药物(Antipsychotic drugs)又称强安定药或神经阻滞剂(Neuroleptic),是一组用于治疗精神分裂症及其它精神病性精神障碍的药物。在通常的治疗剂量并不影响患者的智力和意识,却能有效地控制患者的精神运动兴奋、幻觉、妄想、敌对情绪、思维障碍和异常行为等精神症状。病人通常存在睡眠障碍,常常同时服用镇静安神类药物,为了监测病人体内治疗药物的血药浓度,常需要将这些药物进行快速分离。曲唑酮(Trazodone)是四环类非典型抗抑郁药,具有抗抑郁的作用,以及中枢镇静作用和轻微的肌肉松弛作用,但无抗痉挛和中枢兴奋作用,可改善睡眠,显著缩短抑郁症患者入睡潜伏期,延长整体睡眠时间,提高睡眠质量。氯氮平是属于第二代抗精神病药的药品,基本适应症是精神分裂症,是一些难治性的,其他药物治疗效果不好,不理想的患者是作为二线选择的常用药物。氯氮平也可以用来治疗双向情感障碍,躁狂发作。还有一些老年人出现的意识障碍、意识紊乱、善忘行为,有时候氯氮平治疗也可以起到一定作用。因为氯氮平作用其实比较复杂,产生的不良反应也相对比较多,因此限制了临床广泛使用,所以一般把它作为二线药物来进行使用。去甲氯氮平为氯氮平的代谢产物,也作为重要指标用于临床需要浓度的监测。喹硫平是一种不典型抗精神病药物,对多种神经递质受体有相互作用。主要用于精神分裂症。口服吸收良好、代谢完全,其有效剂量可能较一般人低,使用安全性与其他抗精神病药一样,用于老年人应特别慎重。因此将快速检测这些抗精神病药物并同时实现在线分离具有非常重要的临床应用价值。
但是由于临床病人常常同时服用多种精神基本疾病类药物,高效液相色谱紫外检测方法检测时经常不能完全实现药物的色谱分离,容易存在干扰,影响定量结果;高效液相色谱串联质谱法是以质谱仪为检测手段,集高效液相色谱仪的高分离能力、质谱仪的高灵敏度和高选择性于一体的强有力分析检测工具,质谱作为检测手段虽可以准确定量,但是一方面设备较贵,另一方面同位素内标耗材也非常昂贵且对环境不友好。因此,本领域亟需一种将以上两类药物同时实现在线分离、且分离时间短、效果好的检测方法。
发明内容
为克服现有技术缺陷,本发明采用了以下技术方案:
一种检测体内生物样本中九种精神科药物或其代谢物的试剂盒,包括:
(一)混合标准品溶液TDM检测管,其制备方法包括:将内标溶液、混合标准品溶液加入TDM检测管中,干燥即得;
(二)检测样品溶液TDM检测管,其制备方法包括:将内标溶液加入所述TDM检测管中,干燥即得;
(三)复溶液:含甲酸的甲醇-水溶液;
(四)说明书:所述说明书记载了该试剂盒的使用方法;
且所述试剂盒保存在-20~-15℃下;
进一步的,所述体内生物样本选自血液、血浆、血清、唾液、头发中的任意一种或几种;进一步优选的,所述生物样本为血清或头发;
进一步的,所述九种精神科药物为氨磺必利、氯氮平、去甲氯氮平、奥氮平、米氮平、利培酮、9-OH利培酮、曲唑酮以及喹硫平;
进一步的,所述混合标准品溶液TDM检测管的制备方法包括以下步骤:
S1制备内标溶液为:
S11内标-胃复安工作溶液:精密称定1~30mg胃复安标准品,先用1~30mL甲醇溶解,再用40~70%v/v甲醇-水溶液定容,配制成浓度为0.1~0.5mg/mL的胃复安储备溶液,再用40~70%v/v甲醇-水溶液稀释至10~40μg/mL,即得内标-胃复安工作溶液;
S2制备混合标准品溶液TDM检测管:
S21混标母液的配制:分别精密称定适量神科常用药物或其代谢物氨磺必利、氯氮平、去甲氯氮平、奥氮平、米氮平、利培酮、9-OH利培酮、曲唑酮、喹硫平1~30mg,混合后先用1~30mL溶剂溶解,再用40~70%v/v甲醇-水溶液稀释定容配制成浓度为0.1~0.5mg/mL混标母液;
S22混合标准品溶液的制备:将上述混标母液用40~70v/v%甲醇-水溶液按一定比例稀释,配制成含氨磺必利、氯氮平、去甲氯氮平浓度均为80μg/mL,含奥氮平、米氮平、利培酮、9-OH利培酮浓度均为20μg/mL,含曲唑酮、喹硫平浓度为40μg/mL的定性混合标准品溶液;
S23混合标准品溶液TDM检测管的制备:精密吸取上述混合标准品溶液10~40μL于TDM检测管中,然后加入上述内标-胃复安工作溶液10~40μL,氮气吹干,即得;
进一步的,所述样品溶液TDM检测管的制备方法包括以下步骤:将上述步骤S1制备的内标-胃复安工作溶液10~40μL加入TDM检测管中,氮气吹干,即得;
进一步的,所述复溶液为0.05~0.15v/v%甲酸、浓度为10~20%v/v甲醇-水溶液;
进一步的,所述试剂盒的使用方法:
S1.制备标准品溶液:取上述混合标准品溶液TDM检测管,加入100~1000μL空白血液、血浆、唾液或血清,第一次涡旋1~5min,然后再加入100~500μL的浓度为1~3mol/L的氢氧化钠水溶液以及2~7mL甲基叔丁基醚,第二次涡旋,再以2500~5000r/min离心4~10min,获得上清液,将所述上清液干燥后再加入所述复溶液100~150μL,微孔滤膜过滤,即得;
S2.制备样品检测液:
(2)血液、血浆、唾液或血清样品检测液:取100~1000μL血液、血浆、唾液或血清样本置于样品溶液TDM检测管中,涡旋0.5~2min,再加入100~500μL、浓度为1~3mol/L的氢氧化钠水溶液以及2~7mL甲基叔丁基醚,再次涡旋1~5min,然后以2500~5000r/min离心4~10min,转移上清液到试管中氮气吹干,加入所述复溶液100~150μL,微孔滤膜过滤,即得;
或(2)头发样品检测液:取10~50mg头发样本到样品溶液TDM检测管中,加入100~500μL浓度为1~3mol/L的氢氧化钠水溶液,第一次涡旋0.5~2min,然后超声1~4h,再加入甲基叔丁基醚2~7mL,再进行第二次涡旋2~5min,将涡旋后离心管以速度为2500~5000转/分离心4~10min,转移上清液到试管中,氮气吹干,加入100~150μL复溶液,微孔滤膜过滤,即得;
S3.检测方法:
S31色谱条件:(1)色谱柱:C18色谱柱;(2)流动相:A相为甲酸-水溶液,B相为甲酸-甲醇溶液;(3)检测器为紫外(UV)检测器,优选的,所述紫外检测器为VWD或DAD检测器;进一步优选的,所述紫外检测器的检测波长为254nm、285nm或全波长扫描;
进一步的,S1所述的色谱条件还包括:(4)流动相流速为0.1~0.5mL/min;(5)柱温为35~45℃;(6)工作溶液的进样量均为1.0~20.0μL;
S32测定法:将S1制备的标准品溶液、S2制备的样品检测液分别进样5~10μL注入超高效液相色谱仪,采用梯度洗脱程序:0.00min 5%v/v B、2.00min 15%v/v B、3.50min24%v/v B、6.00min 25%v/v B、7.00min 38%v/v B、8.00min 38%v/v B、9.00min 90%v/v B、10.30min 90%v/v B、11.00min 5%v/v B、13.00min 5%v/v B,得到色谱图,获得所述精神类药物及其代谢物的保留时间tR,即得。
附图说明
图1为采用实施例1的试剂盒检测混合标准品溶液的色谱图
图2为采用实施例1的试剂盒检测服用氯氮平的病人血清样品的色谱图
图3为采用实施例2的试剂盒检测同时服用氯氮平和喹硫平的病人血清样品的色谱图
有益效果
1.本发明采用UPLC-UV法实现了人血清或头发中精神科常用药物及部分活性代谢物的分离;
2.本发明采用内标的分析方法,可以实现快速准确检测,通过向标准品溶液和供试品溶液中加入1个内标物质胃复安同时进样,以准确定位不同保留时间样品峰峰位,仅采用13分钟就实现了多种检测药物的分离,大大缩短了检测时间;且本方法使用的流动相中无添加盐,方便方法切换和色谱柱清洗,同一流动相下可以检测多种药物,方便不同检测方法随时切换,无需更换流动相。
3.本发明采用较为经济的紫外检测器替代使用质谱进行检测,对于指导临床用药以及分析样本具有显著地学术意义和经济价值;
4.本发明通过进一步优化分离条件,例如增加流速、优化洗脱梯度程序,实现短时间内九种药物同时在线分离;
5.本发明采用液-液萃取法、通过加入NaOH溶液提取生物样本(特别是头发)中的有效成分,显著提高了检测限度,且无须昂贵的固相萃取耗材,过滤后进样使色谱柱更耐用,适用于长期大量样本临床检测,具有显著地经济价值;
6.本发明选择特定的复溶液复溶,进一步提高了测量的准确度。
7.本发明进一步优选了过滤滤膜的材质,避免过滤造成损失。
具体实施方式
实施例1:试剂盒检测服用氯氮平的病人血清样品
一种检测血清中四种精神科药物及其代谢物的试剂盒,包括:
(一)混合标准品溶液TDM检测管,其制备方法包括:
S1制备内标溶液为:S11内标-胃复安工作溶液:S211胃复安内标工作溶液:精密称定20mg胃复安标准品于100mL容量瓶中,先用10mL甲醇溶解,再用50%v/v甲醇-水溶液定容,配制成浓度为0.2mg/mL的胃复安储备溶液,再用50%v/v甲醇-水溶液稀释至20μg/mL,即得内标-胃复安工作溶液;
S2制备混合标准品溶液TDM检测管:S21混标母液的配制:分别精密称定适量神科常用药物或其代谢物氨磺必利、氯氮平、去甲氯氮平、奥氮平、米氮平、利培酮、9-OH利培酮、曲唑酮、喹硫平20mg,混合后用10mL甲醇溶解,再用50%v/v甲醇-水溶液定容,分别配制成浓度为0.2mg/mL的标准品母液;S22混合标准品溶液的制备:将上述混标母液用40~70v/v%甲醇-水溶液按一定比例稀释,配制成含氨磺必利、氯氮平、去甲氯氮平浓度为80μg/mL,含奥氮平、米氮平、利培酮、9-OH利培酮浓度为20μg/mL,含曲唑酮、喹硫平浓度为40μg/mL的混合标准品溶液;S23混合标准品溶液TDM检测管的制备:分别精密吸取上述混合标准品溶液20μL于TDM检测管中,然后加入上述内标1-胃复安工作溶液20μL,氮气吹干,即得;
(二)检测样品溶液TDM检测管,其制备方法包括:将上述步骤S1制备的内标-胃复安工作溶液20μL加入TDM检测管中,氮气吹干,即得;
(三)复溶液:所述复溶液为含0.1v/v%甲酸、浓度为15%v/v甲醇-水溶液;
(四)说明书:所述说明书记载了该试剂盒的使用方法;
S1.制备标准品溶液:取上述混合标准品溶液TDM检测管,加入1000μL空白血清,第一次涡旋1min,然后加入200μL的浓度为2mol/L的氢氧化钠水溶液以及3mL甲基叔丁基醚第二次涡旋3min,3000r/min离心5min,获得上清液,将所述上清液干燥后再加入100~150μL复溶液,微孔滤膜过滤,即得;
S2.制备样品检测液:血清样品检测液:精密吸取1000μL待测血清样品置于样品溶液TDM检测管中,第一次涡旋1min,然后加入200μL浓度为2mol/L氢氧化钠水溶液以及甲基叔丁基醚3mL,第二次涡旋3min,再以3000r/min离心5min,取离心后的上清液,氮气吹干后加入200μL含0.1v/v%甲酸、浓度为15%v/v甲醇-水溶液复溶,微孔滤膜过滤,即得;
S3.测定法:将S1制备的标准品溶液、S2制备的样品检测液分别进样5~10μl注入超高效液相色谱仪,采用梯度洗脱程序:0.00min 5%v/v B、2.00min 15%v/v B、3.50min24%v/v B、6.00min 25%v/v B、7.00min 38%v/v B、8.00min 38%v/v B、9.00min 90%v/v B、10.30min 90%v/v B、11.00min 5%v/v B、13.00min 5%v/v B,得到色谱图,获得所述精神类药物及其代谢物的保留时间tR,即得;且所述试剂盒保存在-20~-15℃下。
混合标准品溶液的保留时间tR分别为:奥氮平2.469min、氨磺必利3.033min、胃复安3.443(内标)、米氮平4.257min、9-OH利培酮5.504min、曲唑酮6.091min,利培酮6.410min、去甲氯氮平6.999min、氯氮平7.420min、喹硫平8.022min。
样品内标-胃复安3.444min;试剂盒检测服用氯氮平的病人血清样品保留时间tR分别为:去甲氯氮平7.074min;氯氮平7.477min。
实施例2:采用试剂盒检测同时服用氯氮平和喹硫平的病人血清样品
试剂盒制备和使用方法同实施例1;内标-胃复安的保留时间tR为3.430min;试剂盒检测同时服用氯氮平和喹硫平的病人血清样品保留时间tR分别为:去甲氯氮平7.066min;氯氮平7.471min,喹硫平8.078min。
虽然本发明已以较佳实施例公开如上,但其并非用以限定本发明,任何熟悉此技术的人,在不脱离本发明的精神和范围内,都可做各种的改动与修饰,均在本发明的保护范围内。
Claims (8)
1.一种检测体内生物样本中九种精神科药物或其代谢物的试剂盒,其特征在于,包括:
(一)混合标准品溶液TDM检测管,其制备方法包括:将内标溶液、混合标准品溶液加入TDM检测管中,干燥即得;
(二)检测样品溶液TDM检测管,其制备方法包括:将内标溶液加入所述TDM检测管中,干燥即得;
(三)复溶液:含甲酸的甲醇-水溶液;
(四)说明书:所述说明书记载了该试剂盒的使用方法;
且所述试剂盒保存在-20~-15℃下。
2.根据权利要求1所述的试剂盒,其特征在于,所述体内生物样本选自血液、血浆、血清、唾液、头发中的任意一种或几种;进一步优选的,所述生物样本为血清或头发。
3.根据权利要求1所述的试剂盒,其特征在于,所述九种精神科药物为氨磺必利、氯氮平、去甲氯氮平、奥氮平、米氮平、利培酮、9-OH利培酮、曲唑酮以及喹硫平。
4.根据权利要求1所述的试剂盒,其特征在于,所述混合标准品溶液TDM检测管的制备方法包括以下步骤:
S1制备内标溶液为:
S11内标-胃复安工作溶液:精密称定1~30mg胃复安标准品,先用1~30mL甲醇溶解,再用40~70%v/v甲醇-水溶液定容,配制成浓度为0.1~0.5mg/mL的胃复安储备溶液,再用40~70%v/v甲醇-水溶液稀释至10~40μg/mL,即得内标-胃复安工作溶液;
S2制备混合标准品溶液TDM检测管:
S21混标母液的配制:分别精密称定适量神科常用药物或其代谢物氨磺必利、氯氮平、去甲氯氮平、奥氮平、米氮平、利培酮、9-OH利培酮、曲唑酮、喹硫平1~30mg,混合后先用1~30mL溶剂溶解,再用40~70%v/v甲醇-水溶液稀释定容配制成浓度为0.1~0.5mg/mL混标母液;
S22混合标准品溶液的制备:将上述混标母液用40~70v/v%甲醇-水溶液按一定比例稀释,配制成含氨磺必利、氯氮平、去甲氯氮平浓度均为80μg/mL,含奥氮平、米氮平、利培酮、9-OH利培酮浓度均为20μg/mL,含曲唑酮、喹硫平浓度为40μg/mL的定性混合标准品溶液;
S23混合标准品溶液TDM检测管的制备:精密吸取上述混合标准品溶液10~40μL于TDM检测管中,然后加入上述内标-胃复安工作溶液10~40μL,氮气吹干,即得。
5.根据权利要求1所述的试剂盒,其特征在于,所述样品溶液TDM检测管的制备方法包括以下步骤:将上述步骤S1制备的内标-胃复安工作溶液10~40μL加入TDM检测管中,氮气吹干,即得。
6.根据权利要求1所述的试剂盒,其特征在于,所述复溶液为含0.05~0.15v/v%甲酸、浓度为10~20%v/v甲醇-水溶液。
7.根据权利要求1所述的试剂盒,其特征在于,所述试剂盒的使用方法:
S1.制备标准品溶液:取上述混合标准品溶液TDM检测管,加入100~1000μL空白血液、血浆、唾液或血清,第一次涡旋1~5min,然后再加入100~500μL的浓度为1~3mol/L的氢氧化钠水溶液以及2~7mL甲基叔丁基醚,第二次涡旋,再以2500~5000r/min离心4~10min,获得上清液,将所述上清液干燥后再加入所述复溶液100~150μL,微孔滤膜过滤,即得;
S2.制备样品检测液:
(1)血液、血浆、唾液或血清样品检测液:取100~1000μL血液、血浆、唾液或血清样本置于样品溶液TDM检测管中,涡旋0.5~2min,再加入100~500μL、浓度为1~3mol/L的氢氧化钠水溶液以及2~7mL甲基叔丁基醚,再次涡旋1~5min,然后以2500~5000r/min离心4~10min,转移上清液到试管中氮气吹干,加入所述复溶液100~150μL,微孔滤膜过滤,即得;
或(2)头发样品检测液:取10~50mg头发样本到样品溶液TDM检测管中,加入100~500μL浓度为1~3mol/L的氢氧化钠水溶液,第一次涡旋0.5~2min,然后超声1~4h,再加入甲基叔丁基醚2~7mL,再进行第二次涡旋2~5min,将涡旋后离心管以速度为2500~5000转/分离心4~10min,转移上清液到试管中,氮气吹干,加入100~150μL复溶液,微孔滤膜过滤,即得;
S3.检测方法:
S31色谱条件:(1)色谱柱:C18色谱柱;(2)流动相:A相为甲酸-水溶液,B相为甲酸-甲醇溶液;(3)检测器为紫外(UV)检测器,优选的,所述紫外检测器为VWD或DAD检测器;进一步优选的,所述紫外检测器的检测波长为254nm、285nm或全波长扫描;
S32测定法:将S1制备的标准品溶液、S2制备的样品检测液分别进样5~10μL注入超高效液相色谱仪,采用梯度洗脱程序:0.00min 5%v/vB、2.00min 15%v/v B、3.50min 24%v/v B、6.00min 25%v/v B、7.00min 38%v/v B、8.00min 38%v/v B、9.00min 90%v/vB、10.30min90%v/v B、11.00min 5%v/v B、13.00min 5%v/v B,得到色谱图,获得所述精神类药物及其代谢物的保留时间tR,即得。
8.根据权利要求1所述的试剂盒,其特征在于,S1所述的色谱条件还包括:(4)流动相流速为0.1~0.5mL/min;(5)柱温为35~45℃;(6)工作溶液的进样量均为1.0~20.0μL。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111176732.2A CN113917024B (zh) | 2021-10-09 | 2021-10-09 | 一种检测体内九种精神科药物及其代谢物的试剂盒 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111176732.2A CN113917024B (zh) | 2021-10-09 | 2021-10-09 | 一种检测体内九种精神科药物及其代谢物的试剂盒 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113917024A true CN113917024A (zh) | 2022-01-11 |
CN113917024B CN113917024B (zh) | 2024-07-05 |
Family
ID=79238757
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111176732.2A Active CN113917024B (zh) | 2021-10-09 | 2021-10-09 | 一种检测体内九种精神科药物及其代谢物的试剂盒 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113917024B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117607317A (zh) * | 2023-12-01 | 2024-02-27 | 上海市民政第三精神卫生中心 | 一种测定人血浆中抑郁症药物的方法 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160231341A1 (en) * | 2015-02-05 | 2016-08-11 | Castle Medical, LLC | Multidrug analysis in urine by liquid chromatography-tandem mass spectrometry |
CN109085263A (zh) * | 2018-08-03 | 2018-12-25 | 杭州佰勤医疗器械有限公司 | 液相色谱串联质谱法检测血清血浆中抗精神分裂药物的试剂盒及其应用 |
CN109655568A (zh) * | 2019-01-22 | 2019-04-19 | 杭州度安医学检验实验室有限公司 | 高效液质联用同时测定35种精神药物的方法及试剂盒 |
CN110455945A (zh) * | 2019-08-06 | 2019-11-15 | 北京回龙观医院(北京心理危机研究与干预中心) | 一种检测血液中5种精神药物及其主要代谢产物的方法及试剂盒 |
CN111077239A (zh) * | 2019-11-18 | 2020-04-28 | 沈阳和合医学检验所有限公司 | 一种测定人血清中阿立哌唑、氯氮平、氯丙嗪、利培酮和9-oh利培酮药物浓度的方法 |
CN111257486A (zh) * | 2019-12-31 | 2020-06-09 | 北京回龙观医院(北京心理危机研究与干预中心) | 检测血液中5种精神药物和主要代谢产物的方法及试剂盒 |
CN111812218A (zh) * | 2020-05-29 | 2020-10-23 | 南京品生医学检验实验室有限公司 | 一种同时检测血清中多种抗精神病药物浓度的方法 |
CN112305140A (zh) * | 2020-09-25 | 2021-02-02 | 上海市精神卫生中心(上海市心理咨询培训中心) | 一种检测体内精神药物及其代谢物的方法和应用 |
CN112305134A (zh) * | 2020-11-05 | 2021-02-02 | 北京和合医学诊断技术股份有限公司 | 曲唑酮的检测方法 |
US20220026398A1 (en) * | 2018-10-19 | 2022-01-27 | Human Metabolomics Institute Inc. | Quantitative detection method of multiple metabolites in biological sample and metabolic chip |
-
2021
- 2021-10-09 CN CN202111176732.2A patent/CN113917024B/zh active Active
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160231341A1 (en) * | 2015-02-05 | 2016-08-11 | Castle Medical, LLC | Multidrug analysis in urine by liquid chromatography-tandem mass spectrometry |
CN109085263A (zh) * | 2018-08-03 | 2018-12-25 | 杭州佰勤医疗器械有限公司 | 液相色谱串联质谱法检测血清血浆中抗精神分裂药物的试剂盒及其应用 |
US20220026398A1 (en) * | 2018-10-19 | 2022-01-27 | Human Metabolomics Institute Inc. | Quantitative detection method of multiple metabolites in biological sample and metabolic chip |
CN109655568A (zh) * | 2019-01-22 | 2019-04-19 | 杭州度安医学检验实验室有限公司 | 高效液质联用同时测定35种精神药物的方法及试剂盒 |
CN110455945A (zh) * | 2019-08-06 | 2019-11-15 | 北京回龙观医院(北京心理危机研究与干预中心) | 一种检测血液中5种精神药物及其主要代谢产物的方法及试剂盒 |
CN111077239A (zh) * | 2019-11-18 | 2020-04-28 | 沈阳和合医学检验所有限公司 | 一种测定人血清中阿立哌唑、氯氮平、氯丙嗪、利培酮和9-oh利培酮药物浓度的方法 |
CN111257486A (zh) * | 2019-12-31 | 2020-06-09 | 北京回龙观医院(北京心理危机研究与干预中心) | 检测血液中5种精神药物和主要代谢产物的方法及试剂盒 |
CN111812218A (zh) * | 2020-05-29 | 2020-10-23 | 南京品生医学检验实验室有限公司 | 一种同时检测血清中多种抗精神病药物浓度的方法 |
CN112305140A (zh) * | 2020-09-25 | 2021-02-02 | 上海市精神卫生中心(上海市心理咨询培训中心) | 一种检测体内精神药物及其代谢物的方法和应用 |
CN112305134A (zh) * | 2020-11-05 | 2021-02-02 | 北京和合医学诊断技术股份有限公司 | 曲唑酮的检测方法 |
Non-Patent Citations (7)
Title |
---|
NAGASAKI, T等: "Determination of risperidone and 9-hydroxyrisperidone in human plasma by high-performance liquid chromatography: application to therapeutic drug monitoring in Japanese patients with schizophrenia", JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 31 March 1999 (1999-03-31) * |
SALVATORE FANALI: "HPLC analysis of the antidepressant trazodone and its main metabolite m-CPP in human plasma", JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 31 December 2008 (2008-12-31) * |
侯峰;杨崇俊;张建强;刘冰洁;龙燕怡;: "毛发中8种常见精神类药物的LC-MS/MS检测方法", 中国药物依赖性杂志, no. 06, 15 December 2019 (2019-12-15) * |
张梦琪;贾晶莹;陆晓佩;陆川;曹维锷;李水军;刘罡一;余琛;: "LC-MS/MS同时测定人血清中5种抗精神类药物和9种抗抑郁药物的浓度", 中国药学杂志, no. 01, 8 January 2011 (2011-01-08) * |
杨泽云;李红;: "高效液相色谱法测定血浆中利培酮及9-羟利培酮", 江西医药, no. 07, 20 July 2010 (2010-07-20) * |
段更利,陆明廉,吴柏林: "测定泰必利血药及尿药浓度的反相高效液相色谱法研究", 药学学报, no. 12 * |
温预关, 王玲芝, 刘学军, 陆欣乔: "HPLC法测定人血浆中曲唑酮的浓度", 中国临床药学杂志, no. 01, 25 January 2004 (2004-01-25) * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117607317A (zh) * | 2023-12-01 | 2024-02-27 | 上海市民政第三精神卫生中心 | 一种测定人血浆中抑郁症药物的方法 |
CN117607317B (zh) * | 2023-12-01 | 2024-04-26 | 上海市民政第三精神卫生中心 | 一种测定人血浆中抑郁症药物的方法 |
Also Published As
Publication number | Publication date |
---|---|
CN113917024B (zh) | 2024-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112305140B (zh) | 一种检测体内精神药物及其代谢物的方法和应用 | |
CN113917026B (zh) | 一种检测体内精神科常用药物或其代谢物的方法和应用 | |
CN113917025B (zh) | 一种定量检测生物样本中精神类药物的试剂盒及其应用 | |
CN110068644B (zh) | 高效液相色谱串联质谱测定血浆中奥氮平浓度的方法 | |
CN112946107B (zh) | 一种阿加曲班原料药或制剂中n-亚硝基二甲胺、n-亚硝基二乙胺的分析方法 | |
CN110455945A (zh) | 一种检测血液中5种精神药物及其主要代谢产物的方法及试剂盒 | |
CN113917024A (zh) | 一种检测体内九种精神科药物及其代谢物的试剂盒 | |
CN104749269A (zh) | 一种利用hplc测定阿格列汀原料药及制剂中对映异构体杂质的方法 | |
CN108061767A (zh) | Hplc法分离测定利伐沙班中间体及其相关杂质的方法 | |
Li et al. | Pretreatment of plasma samples by a novel hollow fiber centrifugal ultrafiltration technique for the determination of plasma protein binding of three coumarins using acetone as protein binding releasing agent | |
CN103191116A (zh) | 一种氢溴酸右美沙芬愈创木酚甘油醚口服液及其制备方法 | |
CN117269370A (zh) | 一种同时检测临床样本中14种抗精神药物浓度的方法 | |
Raggi et al. | A rapid LC method for the identification and determination of CNS drugs in pharmaceutical formulations | |
Li et al. | Pharmacokinetic study of three different formulations of l‐tetrahydropalmatine in brain tissues of rats | |
CN113917028A (zh) | 一种检测体内四种精神科药物及其代谢物的试剂盒 | |
Zhang et al. | Comparative brain pharmacokinetic study of Jiaotai pills in normal and insomnic rats using brain microdialysis combinated with LC–MS/MS | |
CN108226314A (zh) | 乙磺酸尼达尼布原料药有关物质的分析检测方法 | |
Ludden et al. | Determination of hydralazine in human whole blood | |
CN109613163B (zh) | 一种酒石酸匹莫范色林及其杂质的检测方法 | |
CN114689767A (zh) | 一种阿立哌唑原料及其制剂有关物质的检测方法 | |
CN112666267B (zh) | 一种阿立哌唑药品有关物质的检测方法 | |
CN114099427B (zh) | 治疗精神疾病的方法和组合物 | |
CN115950992B (zh) | 一种去氧肾上腺素酮咯酸溶液中有关物质的检测方法及其应用 | |
CN113009042B (zh) | 一种3-(1-哌嗪基)-1,2-苯并异噻唑盐酸盐及其有关物质的分析检测方法 | |
CN107290468A (zh) | 一种液质联用定量检测小儿消食片中槟榔碱含量的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Sun Xiujia Inventor after: Li Huafang Inventor after: Zhang Chen Inventor before: Sun Xiujia Inventor before: Zhang Chen Inventor before: Li Huafang |
|
GR01 | Patent grant | ||
GR01 | Patent grant |